NOVOZYMES, GREAT GREEN PLAY BUT WAIT (REDUCE; -9% DOWNSIDE)
20/11/20 -"Novozymes (Reduce, Denmark) is a classic example of a ‘good company at an unattractive price’. We were cautiously optimistic on this Denmark-based enzyme market leader (48% share) when we teased ..."
Pages
54
Language
English
Published on
20/11/20
You may also be interested by these reports :
14/11/25
The Q3 results surpassed expectations, driven by strong demand for depression and migraine medicines. Consequently, the management upgraded its ...
13/11/25
The Q3 results exceeded the street’s expectations, driven by healthy top-line growth across all segments and a profitability beat (also aided by a ...
12/11/25
The Q3 profitability beat was driven by Crop Science, though Pharmaceuticals witnessed lower operating profits. Also, the management maintained its ...
10/11/25
The US government has agreed with Novo and Lilly to lower their weight-loss drugs’ prices, mainly in return for a three-year tariff exemption and ...